Also known as: China Medical System Holdings
China Medical System Holdings is a specialty pharmaceutical company focused on manufacturing, sales, marketing, and promotion of pharmaceutical products in China. It is listed in Hong Kong and has expanded internationally.
Insilico Medicine announced a partnership with China Medical System Holdings for AI-powered drug discovery and nominated ISM5059, an NLRP3-targeted drug candidate, for preclinical development following recent FDA IND approval for another AI-created drug.
China's NMPA approved Desidustat Tablets on March 13, 2026, for treating anemia in non-dialysis CKD patients. Clinical trials showed the oral HIF-PHI was non-inferior to erythropoietin in maintaining hemoglobin levels with improved quality of life.
Insilico Medicine has formed a strategic partnership with Liquid AI to develop lightweight scientific foundation models for drug discovery and entered a drug development collaboration with China Medical System Holdings targeting CNS and autoimmune diseases.
China Medical System Holdings partnered with Insilico Medicine on AI-powered drug discovery in early February 2026 and received Chinese regulatory approval to begin human trials for complement factor B inhibitor CMS-D017.
